Complement Therapeutics
CompanyUnited Kingdom
Complement Therapeutics develops one asset, in phase 1 (CTX001 in anemia). Mostly gene therapy; based in the United Kingdom.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 0
- Signals
Pipeline
1Phase 1, Gene therapy, anemia, chronic kidney disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals2
- Similar companies6